Luminal Breast Carcinoma a disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LMN015 MIFTS: 44	Luminal Breast Carcinoma a Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Luminal Breast Carcinoma a

MalaCards integrated aliases for Luminal Breast Carcinoma a:

Name: Luminal Breast Carcinoma a ¹¹ ¹⁴

Breast Tumor Luminal ¹¹ ¹⁶

Luminal a Breast Carcinoma ¹¹

Luminal Breast Cancer ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0060548

NCIt ⁴⁹ C53554

EFO ¹⁶ EFO_0000306

UMLS ⁷¹ C3642345

Sources

Summaries for Luminal Breast Carcinoma a

Disease Ontology: ¹¹ A breast carcinoma that is characterized by high expression of genes characteristic of luminal epithelial cells, including estrogen receptor (ER), estrogen regulated protein LIV-1, and the transcription factors hepatocyte nuclear factor 3, HNF3A, XBP1, and GATA 3.

MalaCards based summary: Luminal Breast Carcinoma a, also known as breast tumor luminal, is related to estrogen-receptor positive breast cancer and conotruncal heart malformations. An important gene associated with Luminal Breast Carcinoma a is HJURP (Holliday Junction Recognition Protein), and among its related pathways/superpathways are Chromatin Regulation / Acetylation and Chromosome Maintenance. The drugs Palbociclib and Goserelin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone marrow and lymph node, and related phenotypes are Increased Salmonella-containing vacuole maturation and Increased Salmonella enterica Typhimurium binding

Sources

Related Diseases for Luminal Breast Carcinoma a

Diseases in the Luminal Breast Carcinoma a family:

Luminal Breast Carcinoma B

Diseases related to Luminal Breast Carcinoma a via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)

#	Related Disease	Score
1	estrogen-receptor positive breast cancer	10.4
2	conotruncal heart malformations	10.3
3	rhabdomyosarcoma 2	10.1
4	ductal carcinoma in situ	10.1
5	neuroendocrine tumor	10.1
6	breast ductal carcinoma	10.1
7	breast cancer	10.0
8	familial adenomatous polyposis 1	10.0
9	prostate cancer	10.0
10	trichorhinophalangeal syndrome, type i	10.0
11	down syndrome	10.0
12	factor vii deficiency	10.0
13	fanconi anemia, complementation group d2	10.0
14	insulin-like growth factor i	10.0
15	mismatch repair cancer syndrome 1	10.0
16	leukemia, acute myeloid	10.0
17	epidermolysis bullosa simplex superficialis	10.0
18	fanconi anemia, complementation group l	10.0
19	intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies	10.0
20	immunodeficiency, common variable, 10	10.0
21	familial adenomatous polyposis	10.0
22	breast lobular carcinoma	10.0
23	lymphoma	10.0
24	rickets	10.0
25	neutropenia	10.0
26	brain cancer	10.0
27	squamous cell carcinoma	10.0
28	gastric antral vascular ectasia	10.0
29	adenocarcinoma	10.0
30	multiple endocrine neoplasia	10.0
31	breast adenocarcinoma	10.0
32	turner syndrome	10.0
33	tubular adenocarcinoma	10.0
34	severe combined immunodeficiency	10.0
35	48,xyyy	10.0
36	acute myeloid leukemia with recurrent genetic anomaly	10.0

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma a:

Sources

Symptoms & Phenotypes for Luminal Breast Carcinoma a

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased Salmonella-containing vacuole maturation	GR00133-A-2	9.37	CAP1 ITGB5
2	Increased Salmonella enterica Typhimurium binding	GR00133-A-3	9.32	CAP1 ITGB5
3	Increased Salmonella enterica Typhimurium effector injection	GR00133-A-4	9.26	CAP1 ITGB5
4	Increased Salmonella enterica Typhimurium ruffling	GR00133-A-5	9.16	CAP1 ITGB5
5	Increased Salmonella enterica Typhimurium membrane closure	GR00133-A-6	8.96	CAP1 ITGB5
6	Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression	GR00224-A-2	8.62	MED11 MED7

Sources

Drugs & Therapeutics for Luminal Breast Carcinoma a

Drugs for Luminal Breast Carcinoma a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Palbociclib

Approved, Investigational

Phase 3

571190-30-2

5330286

Goserelin

Approved

Phase 3

65807-02-5

5311128 47725

Protein Kinase Inhibitors

Phase 3

Epirubicin

Approved

Phase 2

56420-45-2

41867

Exemestane

Approved, Investigational

Phase 2

107868-30-4

60198

Anastrozole

Approved, Investigational

Phase 2

120511-73-1

2187

Tamoxifen

Approved

Phase 2

10540-29-1, 54965-24-1

2733526

Fulvestrant

Approved, Investigational

Phase 2

129453-61-8

17756771 104741

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Anti-Bacterial Agents

Phase 2

Alkylating Agents

Phase 2

Antirheumatic Agents

Phase 2

Antineoplastic Agents, Alkylating

Phase 2

Antimitotic Agents

Phase 2

Tubulin Modulators

Phase 2

Antibiotics, Antitubercular

Phase 2

Immunosuppressive Agents

Phase 2

Immunologic Factors

Phase 2

Estrogens

Phase 2

Estrogen Receptor Antagonists

Phase 2

Estrogen Antagonists

Phase 2

Hormones

Phase 2

Hormone Antagonists

Phase 2

Antineoplastic Agents, Hormonal

Phase 2

Estrogen Receptor Modulators

Phase 2

Selective Estrogen Receptor Modulators

Phase 2

Albumin-Bound Paclitaxel

Phase 2

Aromatase Inhibitors

Phase 2

Liposomal doxorubicin

Phase 2

Carboplatin

Approved

41575-94-4

10339178 38904

Levoleucovorin

Approved, Experimental, Investigational

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Irinotecan

Approved, Investigational

97682-44-5, 100286-90-6

60838

Fluorouracil

Approved

51-21-8

3385

Oxaliplatin

Approved, Investigational

61825-94-3

43805 11947679 6857599

Interventional clinical trials:

(show all 11)

#	Name	Status	NCT ID	Phase	Drugs
1	Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®	Completed	NCT03447132	Phase 3	Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
2	Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women	Completed	NCT02400567	Phase 2	Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
3	Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer	Completed	NCT01565499	Phase 2	Nab-paclitaxel
4	Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer	Recruiting	NCT04023292	Phase 2	Endocrine therapy
5	SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast): A Phase 2 Study on Fulvestrant Beyond Progression in Combination With Alpelisib for PIK3CA-mutated, Hormone-receptor Positive HER2 Negative Advanced Breast Cancer	Recruiting	NCT05392608	Phase 2	Alpelisib 150 MG Oral Tablet [Piqray];Fulvestrant
6	Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.	Active, not recruiting	NCT03283384	Phase 2	Letrozole;Chemotherapy;Ribociclib plus letrozole
7	Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid	Recruiting	NCT03715959
8	Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients	Recruiting	NCT05580887		mFOLFIRINOX;Doxorubicin;Cyclophosphamid;Paclitaxel;Carboplatin
9	Identification and Monitoring of Resistance to First-line Treatment With CDK 4/6 Inhibitors in Combination With Aromatase Inhibitors in Patients With Metastatic Luminal Breast Cancer Through Non-invasive Biomarkers	Recruiting	NCT04660435
10	Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients	Recruiting	NCT03370250
11	A Clinical Translational Study on the Multi-gene Assays and RecurIndex for Predicting the Breast Cancer Recurrence Risk in Cross-strait Chinese Patients With Early-stage Luminal Breast Cancer	Not yet recruiting	NCT04972448

Search NIH Clinical Center for Luminal Breast Carcinoma a

Sources

Genetic Tests for Luminal Breast Carcinoma a

Sources

Anatomical Context for Luminal Breast Carcinoma a

Organs/tissues related to Luminal Breast Carcinoma a:

MalaCards : Breast, Bone Marrow, Lymph Node, Myeloid, T Cells, Brain, Smooth Muscle

Sources

Publications for Luminal Breast Carcinoma a

Articles related to Luminal Breast Carcinoma a:

(show top 50) (show all 651)

#	Title	Authors	PMID	Year
1	Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods. ⁶²	Lashen A...Rakha E	35997652	2022
2	The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. ⁶²	Waissengrin B...Sonnenblick A	36462463	2022
3	Clinicopathological Features of Breast Cancer in Relation to Exposure of Cycling Reproductive Hormones: A Multicenter Retrospective Study of 14,731 Patients Diagnosed with Invasive Breast Cancer. ⁶²	Sun J...Yang D	36447408	2022
4	Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis. ⁶²	Aylon Y...Oren M	36443319	2022
5	Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers. ⁶²	Kim DS...Kraus WL	35997635	2022
6	Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance. ⁶²	Zhu J...Ohta T	35882754	2022
7	Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. ⁶²	Zou Y...Xie X	36341760	2022
8	A tumor-suppressive function for Notch3 in the parous mammary gland. ⁶²	Chung WC...Xu K	36205077	2022
9	Tinengotinib (TT-00420), a Novel Spectrum-Selective Small Molecule Kinase Inhibitor, Is Highly Active Against Triple Negative Breast Cancer. ⁶²	Peng P...Wu F	36223547	2022
10	Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial. ⁶²	Elia A...Lanari C	36269797	2022
11	Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. ⁶²	Boughey JC...Goetz MP	35876925	2022
12	Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer. ⁶²	Zhang M...Zhang Y	36361541	2022
13	A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer. ⁶²	Wester L...van de Water B	36041543	2022
14	ASO Visual Abstract: Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. ⁶²	Boughey JC...Goetz MP	35871670	2022
15	PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer. ⁶²	Hong J...Xu K	36222718	2022
16	CHD4 mediates SOX2 transcription through TRPS1 in luminal breast cancer. ⁶²	Zhang J...Chen L	36075559	2022
17	Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. ⁶²	Liu Q...Danen EHJ	36077517	2022
18	FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. ⁶²	Groheux D	35636977	2022
19	Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. ⁶²	Battisti NML...Brain E	35777273	2022
20	ASO Visual Abstract: Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer-Effects of Age and Tumor Ki67. ⁶²	Boughey JC...Goetz MP	35776260	2022
21	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. ⁶²	Boughey JC...Goetz MP	35569077	2022
22	FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. ⁶²	Mieczkowski K...Sadej R	35726195	2022
23	Characterization of the Metabolome of Breast Tissues from Non-Hispanic Black and Non-Hispanic White Women Reveals Correlations between Microbial Dysbiosis and Enhanced Lipid Metabolism Pathways in Triple-Negative Breast Tumors. ⁶²	Smith A...Starlard-Davenport A	36077608	2022
24	RUNX1 as a Novel Molecular Target for Breast Cancer. ⁶²	Ariffin NS	35599145	2022
25	The Contribution of Imaging as a Prognostic Marker of Luminal Breast Cancer. ⁶²	Kataoka M	35536138	2022
26	Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy. ⁶²	Kwon BR...Moon WK	35536129	2022
27	FOXF2 oppositely regulates stemness in luminal and basal-like breast cancer cells through the Wnt/beta-catenin pathway. ⁶²	Zhang X...Feng YM	35660418	2022
28	A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer. ⁶²	Elhasnaoui J...De Bortoli M	35887187	2022
29	Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers. ⁶²	Soyama H...Suzuki A	35858357	2022
30	Accelerated Partial Breast Irradiation with Intraoperative Radiotherapy Is Effective in Luminal Breast Cancer Patients Aged 60 Years and Older. ⁶²	Falco M...Pietruszewska J	35887613	2022
31	Ultrasensitive Detection of MCF-7 Cells with a Carbon Nanotube-Based Optoelectronic-Pulse Sensor Framework. ⁶²	Chan SSY...Loke DK	35694527	2022
32	Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. ⁶²	Piccart MJ...Sparano J	35487836	2022
33	GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. ⁶²	Kumegawa K...Maruyama R	35676392	2022
34	Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. ⁶²	Muchlinska A...Zaczek AJ	35690734	2022
35	Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. ⁶²	Yang ZY...Sun G	35717238	2022
36	Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. ⁶²	Delaloge S...French Breast cancer Intergroup Unicancer-UCBG	35337692	2022
37	Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. ⁶²	Pons L...Fernandez PL	35581229	2022
38	Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis. ⁶²	Schreiber C...Sleeman JP	35181478	2022
39	Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1. ⁶²	Abascal MF...Lanari C	34935137	2022
40	Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis. ⁶²	Kemmer S...Timmer J	35625984	2022
41	Pretreatment Leukocyte Count Ratios as Metastatic Predictive Factors in Luminal Type Breast Cancer. ⁶²	Wira Wiguna IGW...Wihandani DM	35633543	2022
42	[Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer]. ⁶²	Sang D...Yuan P	35448926	2022
43	mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease. ⁶²	Wege AK...Brockhoff G	34927257	2022
44	Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer. ⁶²	Thang NX...Hong K	35453496	2022
45	Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. ⁶²	Gombos A...Gebhart G	35296682	2022
46	Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer. ⁶²	Yamamoto S...Endo I	35241543	2022
47	Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms. ⁶²	Ma M...Chen W	34647174	2022
48	[GENOMIC PROFILING IN LUMINAL BREAST CANCER]. ⁶²	Rephael A...Sonnenblick A	35195972	2022
49	New Insights in the Interaction of FGF/FGFR and Steroid Receptor Signaling in Breast Cancer. ⁶²	Perez Pinero C...Lanari C	34977930	2022
50	Machine learning with multiparametric breast MRI for prediction of Ki-67 and histologic grade in early-stage luminal breast cancer. ⁶²	Song SE...Woo OH	34383145	2022

Sources

Genes for Luminal Breast Carcinoma a

Genes related to Luminal Breast Carcinoma a (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HJURP	Holliday Junction Recognition Protein	Protein Coding	6.21	DISEASES inferred ¹⁴
2	ASF1B	Anti-Silencing Function 1B Histone Chaperone	Protein Coding	5.84	DISEASES inferred ¹⁴
3	CENPA	Centromere Protein A	Protein Coding	5.66	DISEASES inferred ¹⁴
4	CHAF1B	Chromatin Assembly Factor 1 Subunit B	Protein Coding	5.21	DISEASES inferred ¹⁴
5	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	5.13	DISEASES inferred ¹⁴
6	CAP1	Cyclase Associated Actin Cytoskeleton Regulatory Protein 1	Protein Coding	5.1	DISEASES inferred ¹⁴
7	MED11	Mediator Complex Subunit 11	Protein Coding	4.73	DISEASES inferred ¹⁴
8	H2BC14	H2B Clustered Histone 14	Protein Coding	4.42	DISEASES inferred ¹⁴
9	ITGB5	Integrin Subunit Beta 5	Protein Coding	4.42	DISEASES inferred ¹⁴
10	MED7	Mediator Complex Subunit 7	Protein Coding	4.4	DISEASES inferred ¹⁴

Sources

Variations for Luminal Breast Carcinoma a

Cosmic variations for Luminal Breast Carcinoma a:

⁸ (show top 50) (show all 5031)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM137960127	ZNF598	breast,NS,carcinoma,ER-PR-positive carcinoma	c.610G>A	p.E204K	16:2002326-2002326	9
2	COSM135195220	ZNF598	breast,NS,carcinoma,ER-PR-positive carcinoma	c.610G>A	p.E204K	16:2002326-2002326	9
3	COSM99169942	YWHAQ	breast,NS,carcinoma,ER-PR-positive carcinoma	c.536A>G	p.Y179C	2:9588211-9588211	9
4	COSM86351284	YWHAQ	breast,NS,carcinoma,ER-PR-positive carcinoma	c.536A>G	p.Y179C	2:9588211-9588211	9
5	COSM143036457	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.918G>A	p.M306I	11:102206008-102206008	9
6	COSM126968360	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.384G>A	p.M128I	11:102206008-102206008	9
7	COSM127993455	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.918G>A	p.M306I	11:102206008-102206008	9
8	COSM85231921	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.918G>A	p.M306I	11:102206008-102206008	9
9	COSM133267649	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.918G>A	p.M306I	11:102206008-102206008	9
10	COSM90942881	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.804G>A	p.M268I	11:102206008-102206008	9
11	COSM145023383	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.804G>A	p.M268I	11:102206008-102206008	9
12	COSM128447016	YAP1	breast,NS,carcinoma,ER-positive carcinoma	c.804G>A	p.M268I	11:102206008-102206008	9
13	COSM105628484	XBP1	breast,NS,carcinoma,ER-positive carcinoma	c.19G>A	p.A7T	22:28800506-28800506	9
14	COSM85917792	XBP1	breast,NS,carcinoma,ER-positive carcinoma	c.19G>A	p.A7T	22:28800506-28800506	9
15	COSM142230116	XBP1	breast,NS,carcinoma,ER-positive carcinoma	c.19G>A	p.A7T	22:28800506-28800506	9
16	COSM89270241	XBP1	breast,NS,carcinoma,ER-positive carcinoma	c.19G>A	p.A7T	22:28800506-28800506	9
17	COSM85182140	WNT2	breast,NS,carcinoma,ER-PR-positive carcinoma	c.321A>G	p.E107=	7:117315338-117315338	9
18	COSM90882705	WNK1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1490A>G	p.K497R	12:859334-859334	9
19	COSM128158629	WNK1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1490A>G	p.K497R	12:859334-859334	9
20	COSM92018095	WNK1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1490A>G	p.K497R	12:859334-859334	9
21	COSM130230128	WNK1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1490A>G	p.K497R	12:859334-859334	9
22	COSM132341362	WNK1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1490A>G	p.K497R	12:859334-859334	9
23	COSM88293154	VHL	breast,NS,carcinoma,ER-positive carcinoma	c.413C>T	p.P138L	3:10146586-10146586	9
24	COSM90651104	VHL	breast,NS,carcinoma,ER-positive carcinoma	c.341-3273G>A	p.?	3:10146514-10146514	9
25	COSM90653783	VHL	breast,NS,carcinoma,ER-positive carcinoma	c.341-3201C>T	p.?	3:10146586-10146586	9
26	COSM88290785	VHL	breast,NS,carcinoma,ER-positive carcinoma	c.341G>A	p.G114D	3:10146514-10146514	9
27	COSM140071241	VAV1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2103G>A	p.K701=	19:6850739-6850739	9
28	COSM130163321	VAV1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2031G>A	p.K677=	19:6850739-6850739	9
29	COSM141193936	VAV1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2034G>A	p.K678=	19:6850739-6850739	9
30	COSM85972860	VAV1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2133G>A	p.K711=	19:6850739-6850739	9
31	COSM142340805	VAV1	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2199G>A	p.K733=	19:6850739-6850739	9
32	COSM88837054	USP9X	breast,NS,carcinoma,ER-PR-positive carcinoma	c.3693A>T	p.R1231S	23:41188000-41188000	9
33	COSM98536780	USP9X	breast,NS,carcinoma,ER-PR-positive carcinoma	c.3693A>T	p.R1231S	23:41188000-41188000	9
34	COSM103478546	USP34	breast,NS,carcinoma,ER-PR-positive carcinoma	c.4201C>A	p.L1401I	2:61296853-61296853	9
35	COSM87092276	USP31	breast,NS,carcinoma,ER-PR-positive carcinoma	c.721C>T	p.H241Y	16:23108096-23108096	9
36	COSM93461611	USP16	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2344C>T	p.P782S	21:29053952-29053952	9
37	COSM103742887	USP16	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2341C>T	p.P781S	21:29053952-29053952	9
38	COSM103747829	USP16	breast,NS,carcinoma,ER-PR-positive carcinoma	c.2344C>T	p.P782S	21:29053952-29053952	9
39	COSM116184328	UQCC5	breast,NS,carcinoma,ER-positive carcinoma	c.*114G>C	p.?	3:52579160-52579160	9
40	COSM127063897	UBR5	breast,NS,carcinoma,ER-PR-positive carcinoma	c.4392C>G	p.F1464L	8:102293802-102293802	9
41	COSM127538052	UBR5	breast,NS,carcinoma,ER-PR-positive carcinoma	c.4374C>G	p.F1458L	8:102293802-102293802	9
42	COSM87429062	UBR5	breast,NS,carcinoma,ER-PR-positive carcinoma	c.4392C>G	p.F1464L	8:102293802-102293802	9
43	COSM144361724	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1803C>T	p.Y601=	15:25356787-25356787	9
44	COSM101929825	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1872C>T	p.Y624=	15:25356787-25356787	9
45	COSM149764169	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1863C>T	p.Y621=	15:25356787-25356787	9
46	COSM108914927	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1803C>T	p.Y601=	15:25356787-25356787	9
47	COSM107120943	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1803C>T	p.Y601=	15:25356787-25356787	9
48	COSM145837560	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1803C>T	p.Y601=	15:25356787-25356787	9
49	COSM135842312	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1803C>T	p.Y601=	15:25356787-25356787	9
50	COSM85309324	UBE3A	breast,NS,carcinoma,ER-PR-positive carcinoma	c.1803C>T	p.Y601=	15:25356787-25356787	9

Sources

Expression for Luminal Breast Carcinoma a

Search GEO for disease gene expression data for Luminal Breast Carcinoma a.

Sources

Pathways for Luminal Breast Carcinoma a

Pathways related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Chromatin Regulation / Acetylation ³	11.54	HJURP CENPA ASF1B
2	Chromosome Maintenance ⁶⁶ Show member pathways Telomere Maintenance ⁶⁶	11.2	HJURP H2BC14 CENPA

Sources

GO Terms for Luminal Breast Carcinoma a

Cellular components related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mediator complex	GO:0016592	9.26	MED7 MED11
2	core mediator complex	GO:0070847	8.92	MED7 MED11

Biological processes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleosome assembly	GO:0006334	9.63	H2BC14 CHAF1B ASF1B
2	CENP-A containing chromatin assembly	GO:0034080	9.13	HJURP CENPA
3	DNA replication-dependent chromatin assembly	GO:0006335	8.92	CHAF1B ASF1B